Back to School: How biopharma can reboot drug development. Access exclusive analysis here
This year, AVNR will start the double-blind, international Phase III STAR trial in about 270 patients with amyotrophic lateral sclerosis (ALS)
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury